You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Recommendations for the treatment of Crohn's disease with tumor necrosis factor antagonists: An expert consensus report
|
|---|---|
| Published in |
Inflammatory Bowel Diseases, October 2011
|
| DOI | 10.1002/ibd.21870 |
| Pubmed ID | |
| Authors |
Brian G. Feagan, Marc Lémann, Ragnar Befrits, William Connell, Geert D'Haens, Subrata Ghosh, Pierre Michetti, Thomas Ochsenkühn, Remo Panaccione, Stefan Schreiber, Mark Silverberg, Dario Sorrentino, C. Janneke van der Woude, Severine Vermeire, Paul Rutgeerts |
| Abstract |
Symptom relief is the traditional treatment goal in Crohn's disease (CD). New goals including mucosal healing and bowel preservation are now achievable with tumor necrosis factor (TNF) antagonists. Infliximab and adalimumab are approved as second-line treatments for severe, active CD. Certolizumab pegol is approved only in the U.S. and Switzerland as second-line treatment for moderate-to-severe, active CD. Data from trials of infliximab suggest that high-risk patients and patients with active inflammation (CRP elevation and/or ileocolonic ulcers) may benefit from earlier use of this drug. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 83 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 2 | 2% |
| United States | 1 | 1% |
| Brazil | 1 | 1% |
| Unknown | 79 | 95% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 19 | 23% |
| Other | 13 | 16% |
| Student > Ph. D. Student | 9 | 11% |
| Student > Postgraduate | 9 | 11% |
| Student > Master | 7 | 8% |
| Other | 16 | 19% |
| Unknown | 10 | 12% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 43 | 52% |
| Agricultural and Biological Sciences | 9 | 11% |
| Computer Science | 2 | 2% |
| Business, Management and Accounting | 2 | 2% |
| Nursing and Health Professions | 2 | 2% |
| Other | 13 | 16% |
| Unknown | 12 | 14% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 30 October 2011.
All research outputs
#19,917,643
of 25,373,627 outputs
Outputs from Inflammatory Bowel Diseases
#3,022
of 3,731 outputs
Outputs of similar age
#124,234
of 153,106 outputs
Outputs of similar age from Inflammatory Bowel Diseases
#41
of 55 outputs
Altmetric has tracked 25,373,627 research outputs across all sources so far. This one is in the 21st percentile – i.e., 21% of other outputs scored the same or lower than it.
So far Altmetric has tracked 3,731 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 7.3. This one is in the 18th percentile – i.e., 18% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 153,106 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 18th percentile – i.e., 18% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 55 others from the same source and published within six weeks on either side of this one. This one is in the 23rd percentile – i.e., 23% of its contemporaries scored the same or lower than it.